ASTELLAS PHARMA UNSP.ADR - Asset Resilience Ratio
ASTELLAS PHARMA UNSP.ADR (YPHA) has an Asset Resilience Ratio of 0.90% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2025)
This chart shows how ASTELLAS PHARMA UNSP.ADR's Asset Resilience Ratio has changed over time. See ASTELLAS PHARMA UNSP.ADR free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down ASTELLAS PHARMA UNSP.ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ASTELLAS PHARMA UNSP.ADR stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €29.94 Billion | 0.9% |
| Total Liquid Assets | €29.94 Billion | 0.90% |
Asset Resilience Insights
- Limited Liquidity: ASTELLAS PHARMA UNSP.ADR maintains only 0.90% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
ASTELLAS PHARMA UNSP.ADR Industry Peers by Asset Resilience Ratio
Compare ASTELLAS PHARMA UNSP.ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Merck & Company Inc
NYSE:MRK |
Drug Manufacturers - General | 0.29% |
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 0.08% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.48% |
|
Biogen Inc
NASDAQ:BIIB |
Drug Manufacturers - General | 2.74% |
|
AstraZeneca PLC
MX:AZNN |
Drug Manufacturers - General | 0.03% |
|
Novartis AG ADR
NYSE:NVS |
Drug Manufacturers - General | 0.08% |
|
AstraZeneca PLC
LSE:AZN |
Drug Manufacturers - General | 0.10% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
Annual Asset Resilience Ratio for ASTELLAS PHARMA UNSP.ADR (2022–2025)
The table below shows the annual Asset Resilience Ratio data for ASTELLAS PHARMA UNSP.ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 0.90% | €29.94 Billion ≈ $35.00 Billion |
€3.34 Trillion ≈ $3.90 Trillion |
+0.09pp |
| 2024-03-31 | 0.81% | €28.78 Billion ≈ $33.65 Billion |
€3.57 Trillion ≈ $4.17 Trillion |
+0.00pp |
| 2023-03-31 | 0.81% | €19.78 Billion ≈ $23.13 Billion |
€2.46 Trillion ≈ $2.87 Trillion |
-0.11pp |
| 2022-03-31 | 0.91% | €21.30 Billion ≈ $24.90 Billion |
€2.33 Trillion ≈ $2.73 Trillion |
-- |
About ASTELLAS PHARMA UNSP.ADR
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia (AML); VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also provides VEOZAH, a treatment for vasomotor symptoms… Read more